title: Factors of importance for a successful delivery system for proteins.
abstract: Protein pharmaceuticals have matured into an important class of drugs, now comprising one in three novel drugs introduced on the market. However, significant gains are still to be made in reducing the costs of production, ensuring proper pharmacokinetics and efficacy, increasing patient compliance and convenience, and reducing side effects such as immunogenicity. This review summarises these issues and provides recent examples of methods to reduce costs, alter pharmacokinetics and increase patient compliance. It also discusses the increasing interest in understanding immunogenicity in order to prevent failure of the protein drug or serious life-threatening side effects due to autoimmunogenicity.
authors.affiliation: The Danish University of Pharmaceutical Sciences, Biomacromolecules Group, Department of Pharmaceutics and Analytical Chemistry, Copenhagen, Denmark. mvdw@dfuni.dk
authors.forename: Marco
authors.initials: M
authors.lastname: van de Weert
authors.forename: Lene
authors.initials: L
authors.lastname: Jorgensen
authors.forename: Eva
authors.initials: E
authors.lastname: Horn Moeller
authors.forename: Sven
authors.initials: S
authors.lastname: Frokjaer
mesh_terms: D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D002626:Chemistry, Pharmaceutical; D004333:Drug Administration Routes; D016503:Drug Delivery Systems; D004355:Drug Stability; D004921:Erythropoietin / Q000008:administration & dosage / Q000276:immunology / Q000493:pharmacokinetics; D006801:Humans; D010349:Patient Compliance; D011506:Proteins / Q000008:administration & dosage* / Q000276:immunology / Q000493:pharmacokinetics; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000276:immunology
chemical_list: D011506:Proteins; D011994:Recombinant Proteins; D004921:Erythropoietin